Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Cervarix in Control Subjects from Primary HPV Study
NCT01249365Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2011
- Primary completion
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Jan 2011; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT01249365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01249365.